ACTINIUM PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$19.50 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-11-14
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$7.58M, a 202.61% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $7.38M.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$14.38M.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was $9.40M.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$3.76M.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$32.62M, a 203.92% decline from fiscal 2022.
- ACTINIUM PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $31.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$19.50M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$12.97M 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | -$7.58M 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | -$3.76M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $1.99M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $9.37M 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | $7.38M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$32.62M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$26.32M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$18.02M 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | -$14.38M 10-Q · filed 2024-04-26 | |||
| 2022-12-31 | $31.39M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $34.29M 10-Q · filed 2023-11-02 | |||
| 2018-09-30 | -$2.55M 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $4.11M 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $9.40M 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | $378.80K 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$8.71M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$3.47M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |